Tumor lysis syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Tumor lysis syndrome}} {{CMG}} ==Overview== ==Prevention== Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas a...")
 
No edit summary
Line 5: Line 5:
==Prevention==
==Prevention==
Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV [[allopurinol]] (a [[xanthine oxidase]] inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). [[Rasburicase]] (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic [[urate oxidase]] enzyme and acts by degrading uric acid. Alkalinization of the urine with [[acetazolamide]] or [[sodium bicarbonate]] is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used.
Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV [[allopurinol]] (a [[xanthine oxidase]] inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). [[Rasburicase]] (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic [[urate oxidase]] enzyme and acts by degrading uric acid. Alkalinization of the urine with [[acetazolamide]] or [[sodium bicarbonate]] is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used.
==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Blood]]
[[Category:Blood]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Hematology]]

Revision as of 14:58, 30 August 2015

Tumor lysis syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tumor lysis syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tumor lysis syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tumor lysis syndrome primary prevention

CDC on Tumor lysis syndrome primary prevention

Tumor lysis syndrome primary prevention in the news

Blogs on Tumor lysis syndrome primary prevention

Directions to Hospitals Treating Tumor lysis syndrome

Risk calculators and risk factors for Tumor lysis syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Prevention

Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV allopurinol (a xanthine oxidase inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). Rasburicase (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic urate oxidase enzyme and acts by degrading uric acid. Alkalinization of the urine with acetazolamide or sodium bicarbonate is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used.

References

Template:WH Template:WS